Literature DB >> 22426316

Does body mass index impact on the relationship between systolic blood pressure and cardiovascular disease?: meta-analysis of 419 488 individuals from the Asia pacific cohort studies collaboration.

Rumi Tsukinoki1, Yoshitaka Murakami, Rachel Huxley, Takayoshi Ohkubo, Xianghua Fang, Il Suh, Hirotsugu Ueshima, Tai-Hing Lam, Mark Woodward.   

Abstract

BACKGROUND AND
PURPOSE: Elevated blood pressure and excess body mass index (BMI) are established risk factors for cardiovascular disease (CVD) but controversy exists as to whether, and how, they interact.
METHODS: The interactions between systolic blood pressure and BMI on coronary heart disease, ischemic and hemorrhagic stroke and CVD were examined using data from 419 448 participants (≥ 30 years) in the Asia-Pacific region. BMI was categorized into 5 groups, using standard criteria, and systolic blood pressure was analyzed both as a categorical and continuous variable. Cox proportional hazard models, stratified by sex and study, were used to estimate hazard ratios, adjusting for age and smoking and the interaction was assessed by likelihood ratio tests.
RESULTS: During 2.6 million person-years of follow-up, there were 10 877 CVD events. Risks of CVD and subtypes increased monotonically with increasing systolic blood pressure in all BMI subgroups. There was some evidence of a decreasing hazard ratio, per additional 10 mm Hg systolic blood pressure, with increasing BMI, but the differences, although significant, are unlikely to be of clinical relevance. The hazard ratio for CVD was 1.34 (95% CI, 1.32-1.36) overall with individual hazard ratios ranging between 1.28 and 1.36 across all BMI groups. For coronary heart disease, ischemic stroke, and hemorrhagic stroke, the overall hazard ratios per 10 mm Hg systolic blood pressure were 1.24, 1.46, and 1.65, respectively.
CONCLUSIONS: Increased blood pressure is an important determinant of CVD risk irrespective of BMI. Although its effect tends to be weaker in people with relatively high BMI, the difference is not sufficiently great to warrant alterations to existing guidelines.

Entities:  

Mesh:

Year:  2012        PMID: 22426316     DOI: 10.1161/STROKEAHA.112.650317

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  5 in total

1.  Ambulatory blood pressure monitoring for risk stratification in obese and non-obese subjects from 10 populations.

Authors:  T W Hansen; L Thijs; Y Li; J Boggia; Y Liu; K Asayama; M Kikuya; K Björklund-Bodegård; T Ohkubo; J Jeppesen; C Torp-Pedersen; E Dolan; T Kuznetsova; K Stolarz-Skrzypek; V Tikhonoff; S Malyutina; E Casiglia; Y Nikitin; L Lind; E Sandoya; K Kawecka-Jaszcz; J Filipovský; Y Imai; J Wang; E O'Brien; J A Staessen
Journal:  J Hum Hypertens       Date:  2014-01-16       Impact factor: 3.012

2.  Plasma growth differentiation factor 15 predicts first-ever stroke in hypertensive patients.

Authors:  Xiaojian Wang; Ling Zhu; Yan Wu; Kai Sun; Ming Su; Liping Yu; Jingzhou Chen; Weiju Li; Jing Yang; Zuyi Yuan; Rutai Hui
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

3.  Clustering of risk factors and the risk of incident cardiovascular disease in Asian and Caucasian populations: results from the Asia Pacific Cohort Studies Collaboration.

Authors:  Sanne A E Peters; Xin Wang; Tai-Hing Lam; Hyeon Chang Kim; Suzanne Ho; Toshiharu Ninomiya; Matthew Knuiman; Ilonca Vaartjes; Michael L Bots; Mark Woodward
Journal:  BMJ Open       Date:  2018-03-06       Impact factor: 2.692

4.  Short-term Increase in Risk of Overweight and Concomitant Systolic Blood Pressure Elevation in Treatment-Naïve Persons Starting INSTI-Based Antiretroviral Therapy.

Authors:  Ronald Galdamez; José A García; Marta Fernández; Catalina Robledano; Vanessa Agulló; Javier García-Abellán; Guillermo Telenti; Sergio Padilla; Félix Gutiérrez; Mar Masiá
Journal:  Open Forum Infect Dis       Date:  2019-11-13       Impact factor: 3.835

5.  Meta-analyses using individual participant data from cardiovascular cohort studies in Japan: current status and future directions.

Authors:  Yoshitaka Murakami
Journal:  J Epidemiol       Date:  2014-03-01       Impact factor: 3.211

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.